VIVITROL

Compare VIVITROL  to:
Compare
Compare

Generic Name for VIVITROL

Naltrexone 380mg/vial; ext-rel susp for IM inj.

Legal Classification:

Rx

Pharmacological Class for VIVITROL

Opioid antagonist.

Manufacturer of VIVITROL

Alkermes

Indications for VIVITROL

Alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting, in conjunction with psychosocial support (eg, counseling or group therapy).

Adult dose for VIVITROL

Give by IM inj into alternating buttocks. 380mg once every 4 weeks.

Children's dosing for VIVITROL

Not recommended.

Contraindications for VIVITROL

Concomitant opioids. Current physiologic opioid dependence. Acute opiate withdrawal. Failed naloxone challenge test. Positive urine test for opioids. Acute hepatitis. Liver failure.

Precautions for VIVITROL

Active liver disease (monitor closely). Discontinue if hepatitis develops. Consider naloxone challenge test before treating to exclude recent (7–10 days) opioid use. Moderate to severe renal dysfunction. Coagulation disorders. Risk of eosinophilic pneumonia; follow-up if respiratory symptoms occur. Monitor for depression and/or suicidality. Advise patient of reduced post-treatment opioid tolerance and of danger of attempting to overcome opioid blockade; advise use of medication alert documentation. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for VIVITROL

See Contraindications. Antagonizes opioids (eg, antitussives, antidiarrheals, analgesics); use non-opioids, and/or anesthesia if pain management is necessary. May interfere with urine opioid tests.

Adverse Reactions for VIVITROL

GI upset, fatigue, headache, dizziness, decreased appetite, inj site reactions (may be serious; eg, induration, cellulitis, hematoma, abscess, sterile abscess, necrosis), hepatotoxicity (overdosage); rare: allergic (eosinophilic) pneumonia.

How is VIVITROL supplied?

Vial—1 (w. supplies)

Related Disease:

Alcoholism

Related Resources

Phase 3 study of extended-release injectable naltrexone for treatment of opioid dependence

November 16, 2009

Alkermes Inc. announced positive preliminary results from a Phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence.

FDA halts marketing of unapproved nitroglycerin tablets

March 17, 2010

The FDA has ordered Glenmark Generics and Konec Inc. to stop marketing unapproved nitroglycerin tablets.

Hibiclens General Skin Cleansing Patient Kit available

March 17, 2010

Molnlycke Health Care announced the launch of Hibiclens General Skin Cleansing Patient Kit that is to be used at home prior to surgery as part of a strategy to minimize surgical-site infections and hospital-acquired infections.

Neosalus Cream available for dermatitis

March 16, 2010

Quinnova announced the launch of Neosalus Cream, a non-steroidal anti-inflammatory cream for the treatment of various dermatoses (eg, atopic dermatitis, contact dermatitis, and hand eczema).

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.